Current:Home > MyALS drug's approval draws cheers from patients, questions from skeptics-LoTradeCoin
ALS drug's approval draws cheers from patients, questions from skeptics
View Date:2024-12-23 19:58:25
The Food and Drug Administration has approved a controversial new drug for the fatal condition known as ALS, or Lou Gehrig's disease.
The decision is being hailed by patients and their advocates, but questioned by some scientists.
Relyvrio, made by Amylyx Pharmaceuticals of Cambridge, Mass., was approved based on a single study of just 137 patients. Results suggested the drug might extend patients' lives by five to six months, or more.
"Six months can be someone attending their daughter's graduation, a wedding, the birth of a child," says Calaneet Balas, president and CEO of the ALS Association. "These are really big, monumental things that many people want to make sure that they're around to see and be a part of."
Balas says approval was the right decision because patients with ALS typically die within two to five years of a diagnosis, and "right now there just aren't a lot of drugs available."
But Dr. David Rind, chief medical officer for the Institute for Clinical and Economic Review, isn't so sure about Relyvrio, which will cost about $158,000 a year.
"I totally understand why people would be trying to figure out a way to get this to patients," he says. "There's just a general concern out there that maybe the trial is wrong."
ALS kills about 6,000 people a year in the U.S. by gradually destroying nerve cells that control voluntary movements, like walking, talking, eating, and even breathing. Relyvrio, a combination of two existing products, is intended to slow down the disease process.
Proponents of the drug say the small trial showed that it works. But FDA scientists and an expert panel that advises the FDA, weren't so sure.
Typically, FDA approval requires two independent studies – each with hundreds of participants – showing effectiveness, or one large study with clearly positive results.
In March, the Peripheral and Central Nervous System Drugs Advisory committee concluded that the Amylyx study did not provide "substantial evidence" that its drug was effective. Then in September, during a rare second meeting to consider a drug, the panel reversed course and voted in favor of approval.
The second vote came after Dr. Billy Dunn, director of the FDA's Office of Neuroscience, encouraged the committee to exercise "flexibility" when considering a drug that might help people facing certain death.
A much larger study of Relyvrio, the Phoenix Trial, is under way. But results are more than a year off.
A negative result from that study would be a major blow to Amylyx and ALS patients.
"If you've got a drug that's extending life by five months," Rind says, "you ought to be able to show that in a larger trial."
In the meantime, he says, perhaps Amylix should charge less for their drug.
Relyvrio (marketed as Albrioza in Canada) is the only product made by Amylyx, a company founded less than a decade ago by Joshua Cohen and Justin Klee, who attended Brown University together.
Klee defends the drug's price, saying it will allow the company to develop even better treatments. "This is not a cure," he says. "We need to keep investing until we cure ALS."
Klee and Cohen have also promised that Amylyx will re-evaluate its drug based on the results of the Phoenix trial.
"If the Phoenix trial is not successful," Klee says, "we will do what's right for patients, which includes taking the drug voluntarily off the market."
But that the decision would require support from the company's investors, and its board of directors.
veryGood! (9598)
Related
- 2 Florida women charged after shooting death of photographer is livestreamed
- A Russian spacecraft crashed on the moon last month. NASA says it's discovered where.
- Missing Colorado climber found dead in Glacier National Park, cause of death under investigation
- Police search for suspect who shot and wounded person at Indiana shopping mall
- Mike Tyson emerges as heavyweight champ among product pitchmen before Jake Paul fight
- Burning Man 2023: With no estimate of reopening time, Burners party in the rain and mud
- Lionel Messi, Inter Miami face Los Angeles FC in MLS game: How to watch
- Police search for suspect who shot and wounded person at Indiana shopping mall
- 2 more escaped monkeys recaptured and enjoying peanut butter and jelly sandwiches in South Carolina
- Kevin Costner Accuses Estranged Wife Christine of Relentless Hostility Amid Divorce Court Hearing
Ranking
- Larry Hobbs, who guided AP’s coverage of Florida news for decades, has died at 83
- Russia says it thwarted attacks on Crimea bridge, which was briefly closed for a third time
- Stakes are high for Michigan Wolverines QB J.J. McCarthy after playoff appearance
- September Surge: Career experts disagree whether hiring surge is coming in 2023's market
- How Alex Jones’ Infowars wound up in the hands of The Onion
- Russia attacks a Ukrainian port before key grain deal talks between Putin and Turkey’s president
- Why Coco Gauff vs. Caroline Wozniacki is the must-see match of the US Open
- Nick Saban takes Aflac commercials, relationship with Deion Sanders seriously
Recommendation
-
NBC's hospital sitcom 'St. Denis Medical' might heal you with laughter: Review
-
The Second Prince: Everything We Know About Michael Jackson's Youngest Child, Bigi
-
Typhoon Saola makes landfall in southern China after nearly 900,000 people moved to safety
-
Midwestern 'paradise for outdoor enthusiasts': See Indiana's most unique estate for sale
-
US Election Darkens the Door of COP29 as It Opens in Azerbaijan
-
Is UPS, USPS, FedEx delivering on Labor Day? Are banks, post offices open? What to know
-
Shooting at Louisiana high school football game kills 1 person and wounds another, police say
-
Workers are finally seeing real wage gains, but millions still struggle to pay the bills